Introduction
HIV is a uniquely challenging pathogen for humans due to its high-replication capacity and mechanisms of evading antiviral immunity in the absence of antiretroviral therapies (ART). In addition, the ability to cease replication and become latent in CD4 T cells (mainly memory CD4 T cells) and macrophages during virally suppressive ART allows escape from the immune response. Infected memory CD4 T cells and macrophages are constantly trafficking throughout lymphoid and non-lymphoid tissues, and depending on the tissue microenvironment, the HIV provirus can re-initiate replication or remain latent. Lymphoid tissues, particularly lymph nodes, spleen, and gut-associated lymphoid tissues (GALT) comprise major tissue reservoirs for HIV, but other tissues such as brain, lungs, liver, bone marrow, and reproductive tissues also represent important reservoir sites with unique immunological and pharmacological sanctuary characteristics that promote HIV persistence.
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More recently, in large part due to increasing research interest on obesity and metabolic disorders and associated chronic inflammation, adipose tissue has been investigated as a reservoir for HIV-infected immune cells. Following seminal reports demonstrating significant accumulation of macrophages and T cells in adipose tissue in murine models of obesity, further studies of adipose-resident immune cells provided strong rationale that such immunological phenomena could be important for HIV pathogenesis and reservoir dynamics [1, 2] . Earlier studies showed that interactions between immune cells and adipocytes, specifically perinodal adipocytes, promote immune activation and adipose inflammation, suggesting adipocyte regulation of HIV replication and pathogenesis [3, 4] . Although adipose tissue health and function in HIV patients have been extensively studied over the past couple of decades, particularly in the context of antiretroviral therapy and metabolism, studies more directly focused on immune cells and HIV infection in adipose tissue have only recently been reported. An overview of these studies is provided in Table 1 , which provides clear evidence of HIV and SIV reservoir establishment in adipose tissue of humans and monkeys. This review examines the evidence describing adipose tissue as reservoirs for HIV and the elements that make this compartment an important contributor of persistent HIV.
Adipose Tissue: A Reservoir for Diverse Microbes
Although the primary focus of this review is HIV in adipose tissue, it is important to note that adipose tissue harbors other pathogens, particularly parasites and bacteria, each deriving benefit from and affecting adipocytes in unique ways. Parasites such as Trypanosoma cruzi, Trypanosoma brucei, and Plasmodium spp. infiltrate adipose tissue and reside in extracellular spaces or directly infect adipocytes of humans or mice, which have been excellently reviewed [12, 13] . A number of studies have described infection of human and murine adipocytes by bacteria, including Mycobacterium tuberculosis, Enterococcus faecalis, Staphylococcus aureus, and Rickettsia prowazekii [14] [15] [16] [17] [18] [19] . With respect to viruses, cytomegalovirus and adenovirus 36 can infect human, murine, or primate adipocyte progenitor stem cells and mature adipocytes, and Adv36 infection has been associated with weight gain and obesity [20] [21] [22] [23] [24] [25] [26] . The consequence of these pathogens residing in adipose tissue is to increase adipocyte inflammation and dysfunction, immune cell activation, long-term microbial persistence, and protection from anti-microbial compounds. The microbial composition in adipose tissue, particularly visceral fat, is further altered because of intestinal breaching and microbial translocation [27] [28] [29] . It remains to be determined whether the coexistence of other pathogens Only two patients were positive for HIV DNA, and none were positive for HIV RNA in adipose tissue samples. However, this study was published prior to the initial reports demonstrating the presence of macrophages and T cells in adipose tissue in mouse models of obesity, and before methods to study adipose tissue and specific cellular subsets, such as separation of adipocytes and AT-SVF cells, were better developed [1, 2] . Murine models would later demonstrate migration of immune cells into adipose tissue to become major regulators of adipocyte function and metabolism, and studies of healthy and diseased humans further showed significant accumulation of immune cells [30] [31] [32] [33] . Additionally, virion-free circulating HIV proteins, such as vpr, nef, and tat, were shown to mediate detrimental effects on adipose tissue health and systemic metabolism [34] [35] [36] [37] [38] [39] [40] [41] . In light of findings such as these and the need to better understand HIV tissue reservoirs and latency, the question of HIV persistence in adipose tissue is of high significance.
HIV or SIV proviral DNA and RNA is present mainly in CD4 T cells in adipose tissue of infected humans or monkeys, and viral DNA is replication-competent and infectious by RNAscope that infected CD4 T cells were sparsely distributed throughout subcutaneous and visceral adipose tissues with infrequent detection [6••] . Measurement of RNA by RT-PCR additionally showed that SHIV RNA was significantly lower in adipose tissue samples compared to lymph node and intestinal tissues, whereas viral DNA was not measured. The use of humanized mouse models to study adipose tissue during HIV infection is yet to be conducted but may be useful in further characterizing immune cells, viral replication, and antiretroviral distribution in adipose tissue, although the obvious concern with respect to studying adipocyte-immune cell interactions is the adipocytes being of murine origin.
Lastly, although many non-hematopoietic cells, such as epithelial cells and astrocytes, can be productively infected by HIV to minor extents, human preadipocytes and adipocytes do not express the HIV entry receptors CD4, CCR5, and CXCR4 and are incapable of being productively infected [8••, 42] . Additionally, by contrast to bone marrow hematopoietic stem cells which can be infected with HIV, mesenchymal stem cells derived from human adipose tissue do not support productive HIV infection, although they can be productively infected if differentiated into hematopoietic cells [43] . Thus, CD4 T cells and macrophages are likely to be the only cells infected with HIV in adipose tissue. Altogether, these findings suggest that HIV/SIV-infected CD4 T cells, and to a lesser extent infected macrophages, accumulate in adipose tissue during acute and chronic infection despite antiretroviral treatment, but may persist mostly in a transcriptionally dormant state, which is problematic for HIV cure efforts that rely on viral reactivation.
Composition and Functions of Immune Cells in Adipose Tissue During HIV/SIV Infection and Impact on Adipocyte Health and Metabolism
The phenotypes and functions of CD4 and CD8 T cells, macrophages, natural killer, and NKT cells in adipose tissue of HIV/SIV-infected humans or monkeys have been studied, although the specific subsets of adipose-resident CD4 T cells and macrophages infected with HIV are not as wellcharacterized as for those in other tissues such as lymph nodes (i.e., CD4+CXCR5+PD1+ T follicular helper cells). A number of studies have described B cell accumulation in adipose tissue of obese mice and humans, but B cells have not been extensively studied in adipose tissue of HIV patients or infected monkeys [8••, 9••, [44] [45] [46] . Additionally, dendritic cells and granulocytes, such as neutrophils, eosinophils, and mast cells infiltrate adipose tissue and regulate adipocyte function and metabolism in mice and humans, but the presence of these cells in adipose tissue during HIV/SIV infection has not been determined [47] [48] [49] [50] [51] [52] . Another outstanding question pertains to the signals and chemoattractants mediating infiltration of infected immune cells into adipose tissue during HIV infection, although studies of mice and humans, mostly in the context of obesity, suggest that a number of chemokine receptors, including CXCR3, CCR1, CCR2, CCR5, CCR6, and CCR7, are important for T cell and macrophage migration and retention in adipose tissue [53] [54] [55] [56] [57] [58] [59] [60] [61] .
Current In addition, the proportion of CD206-CD163-proinflammatory macrophages was increased compared to uninfected monkeys. In concert with the HIV/SIV RNA evidence indicating low levels of viral replication in adipose tissue CD4 T cells, these studies suggest that mechanisms of antiviral immunity may be adequate in controlling viral replication, although not sufficient to prevent viral reservoir establishment or to eradicate infected immune cells from adipose tissue. Other mechanisms of antiviral immunity, including TLR signaling and type I interferons, are also likely to contribute towards viral suppression in adipose tissue.
Despite the viral RNA data suggesting that minimal levels of HIV replication occur in adipose tissue CD4 T cells, and the infected human and monkey data suggesting that adiposeresident T cells overall may be less activated relative to T cells in other viral reservoir tissues, in vitro and in vivo studies show that adipocytes can stimulate adipose-resident T cells to promote HIV replication. In vitro co-culture experiments between HIV-infected CD4 T cells and primary human adipocytes show that adipocytes enhance IL2-, IL7-, or IL15-induced T cell activation and HIV replication, mediated by IL6 and integrin ligands [10••] . Adipose tissue macrophages activate adipose-resident CD4 T cells via class II MHC, but more surprisingly, adipocytes of obese humans and mice also express class II MHC and activate adipose-resident CD4 T cells [76] [77] [78] [79] . Other in vitro co-culture studies between human adipocytes and CD4 T cells showed that adipocytes increased T cell activation and proliferation, also mediated in part by class II MHC mechanisms, as well as free fatty acids [80, 81] . Adipocytes also release exosomes which regulate metabolic pathways and disease pathogenesis, and separate studies have additionally shown that exosomes can reactivate latent HIV in CD4 T cells [82] [83] [84] [85] [86] [87] .
The consequences of HIV replication in adipose-resident immune cells upon adipocyte function are implicated by a number of studies demonstrating that soluble viral proteins such as vpr, nef, and tat negatively impact adipocyte biology. The HIV accessory protein vpr has been the most extensively studied with respect to their effects on adipocyte function. Shrivastav et al. showed that vpr transduces 3T3-L1 murine preadipocytes, antagonizes PPARγ function, and suppresses expression of critical adipocyte differentiation genes [88] . In mouse models exposed to vpr via transgenic expression, direct injections, or ALZET osmotic pumps, Balasubramanyam et al. and Agarwal et al. further demonstrated that vpr impairs adipocyte growth and function, increases adipose inflammation, dysregulates systemic lipid metabolism, and promotes fatty liver disease [34, 39, 40] . Importantly for HIV-infected quiescent CD4 T cells in different tissue reservoirs, circulating vpr can also reactivate latent provirus [89, 90] . Adipocytes exposed to tat and nef in vitro also result in suppression of PPARγ function and adipogenesis, as well as upregulation of inflammatory cytokines and impairment of glucose uptake [35, 37, 38] . In SIVinfected rhesus macaques, Asztalos et al. showed that circulating nef dysregulates lipid metabolism by localizing to the liver and inhibiting cholesterol efflux pathways in infected macrophages and hepatocytes [36] . In acutely (four weeks) and chronically (38 weeks) infected rhesus macaques not treated with antiretroviral drugs, expression of genes critical for adipocyte function, including C/EBPα, leptin, and GLUT4, was downregulated compared to uninfected monkeys [8••] . Infected monkeys additionally experienced dyslipidemias as indicated by altered serum levels of triglycerides and free fatty acids, consistent with metabolic abnormalities in HIV patients.
In chronically infected macaques, Damouche et al. showed that the density of adipocytes and AT-SVF cells was significantly increased compared to uninfected monkeys, suggestive of abnormal patterns of growth and differentiation of fat cells [9••] . Antiretrovirals are major regulators of adipose tissue function and metabolism in HIV patients, but in light of the recent studies demonstrating establishment of HIV reservoirs in adipose tissue and the potential proviral induction capacity by adipocytes, the mechanisms of adipocyte dysfunction mediated directly by infected immune cells and soluble viral proteins have become more important.
Antiretroviral Therapy and Adipose Tissue
Systemic distribution of HIV antiretroviral drugs is critical for viral suppression, and the improvement of antiretroviral pharmacology and modes of delivery is currently being intensely investigated. Despite the successes of cART, latently infected immune cells persist in pharmacological sanctuary sites such as lymph nodes, GALT, brain, and reproductive tissues such that HIV likely undergoes transient low-level replication. In lymph nodes of cART-treated patients, viral persistence is associated with lower levels of antiretroviral drug penetration relative to other tissues such as PBMC and serum, and in the brain, certain drugs are excluded by the blood-brain barrier. Fletcher et al. showed that the intracellular concentrations of nucleoside/nucleotide reverse transcriptase inhibitors (tenofovir and emtricitabine), non-nucleoside reverse transcriptase inhibitor (efavirenz), and protease inhibitors (atazanavir and darunavir) in lymph nodes of HIV patients were significantly lower compared to PBMCs, and these lower drug levels were further associated with viral replication in lymph nodes [91] . Whether adipose tissue represents a pharmacological sanctuary for HIV is currently unclear, but available evidence suggests the possibility depending on the antiretroviral regimen.
The impact of antiretroviral therapy upon adipose tissue health and metabolism is extensively studied, but the study by Dupin et al. is the only study which directly investigated drug distribution in adipose tissue of HIV patients [11•] . In the study, lysates of whole adipose tissue samples were examined by LC/MS for the presence of protease inhibitors (PIs), nucleoside reverse transcriptase inhibitors (NRTIs), and nonnucleoside reverse transcriptase inhibitors (NNRTIs). Integrase inhibitors (INSTIs) were not examined as this study was conducted prior to FDA approval for raltegravir in 2007. A clear drug class-specific distribution was observed in which NRTIs were below detection limits in adipose tissue samples of all patients, levels of PIs were minimal to undetectable (<2 nmol/g), and NNRTIs were present in significant amounts (~38-285 nmol/g). The authors of the present review are also currently investigating antiretroviral distribution in adipose tissue of HIV patients and SHIV-infected rhesus monkeys and have obtained similar data (unpublished observations). Consistent with the findings of Dupin et al. in which whole adipose tissue lysates were studied, we have observed a lack of N(t)RTI penetration in BOTH separated adipocytes and AT-SVF samples of HIV patients and rhesus monkeys, whereas NNRTIs are detectable in fat samples. Most intriguingly, we have observed significant penetration of INSTIs including dolutegravir and elvitegravir in adipocytes and AT-SVF cells (a subject on raltegravir has not yet been studied), which in conjunction with the findings of Dupin et al. suggest that NNRTIs and INSTIs enter adipose tissue, whereas PIs and N(t)RTIs are more restricted. We have additionally observed in in vitro co-culture experiments that adipocytes can negatively affect antiretroviral efficacy, mediated in part by significant uptake and sequestration of drugs by adipocytes, consistent with other in vitro studies demonstrating rapid and significant uptake of antiretrovirals by adipocytes [92, 93] .
Intriguingly, Damouche et al. showed that CD4 T cells in adipose tissue of SIV-infected monkeys were localized significantly more distal to blood vessels compared to CD8 T cells, suggesting that distribution of antiretroviral drugs to infected CD4 T cells in adipose tissues could be more challenging, particularly if drugs are rapidly sequestered and metabolized by adipocytes and other AT-SVF cells [9••] . Significant uptake of antiretroviral drugs by adipocytes would be another impediment for drug distribution in other tissues as adipocytes can accumulate in HIV reservoir sites such as lymph nodes, bone marrow, liver, and GALT. Expression of drug transporters by adipocytes, AT-SVF cells, and adipose-resident immune cells is another consideration for drug distribution as these cells express influx and efflux transporters including P-glycoprotein, multidrug resistance proteins, equilibrative nucleoside transporters, and breast cancer resistance proteins, which regulate cellular antiretroviral uptake and retention [94] [95] [96] [97] . Antiretroviral pharmacology is regulated by a number of factors including half-life, protein binding, lipophilicity, intracellular metabolism, and drug transporters, and many of these elements so far appear to be relevant in adipose tissue.
In the context of other microbial infections and diseases, adipocytes reduce the efficacy of therapeutic compounds. For example, M. tuberculosis and T. cruzi persist in adipose tissue of humans and mice despite antibiotic treatments [14, 18, 19, 98] [18, 98] . Lastly, extensive research has established that adipocytes significantly influence tumor progression and cancer biology [99] [100] [101] . Adipocytes crosstalk with tumor cells to promote growth and metastases and further enhance chemotherapeutic resistance by impairing mechanisms of tumor cell killing and sequestering drugs. For example, trastuzumab is a critical antibody-based chemotherapeutic against breast cancer which mediates tumor cell killing by natural killer cells and ADCC mechanisms, and adipocytes suppress such tumor cell killing by secreting factors that impair NK cell functions [102] . Additionally, daunorubicin is another important chemotherapeutic for leukemias and adipocytes enhance survival of acute lymphoblastic leukemia cells by secreting factors which protect the tumor cells from oxidative stress, as well as by sequestering and inactivating significant amounts of daunorubicin [103, 104] . Lastly, human T-cell acute lymphoblastic leukemia (T-ALL) cancer cells transplanted into mice accumulate in gonadal adipose tissue of mice and adopt enhanced chemoresistance profiles similar to T-ALL cells in bone marrow sites rich in adipocytes, and adipose T-ALL cells furthermore became more resistant to vincristine when co-cultured with adipocytes in vitro [105] . These studies further highlight the dynamic nature of adipocytes and interaction with other cells beyond metabolism.
The characterization of adipose tissue as a pharmacological sanctuary for HIV requires further investigation, but available evidence suggests that penetration of antiretroviral drugs into adipose tissue is class-specific, in which NNRTIs and INSTIs may be significantly more fat-soluble compared to PIs and N(t)RTIs. This is important for the HIV reservoir in adipose tissue as N(t)RTIs typically constitute the "backbone" of most antiretroviral regimens. The distribution and pharmacology of antiretroviral drugs in adipose tissue continue to be investigated in our laboratory, as well as in ongoing clinical trials being conducted by other investigators, and the findings from these studies will enhance our understanding of antiretroviral pharmacology, particularly in lipid-rich tissues with high metabolic activity. Additionally, as it is now clear that adipose tissue harbors latently infected immune cells, it will also be important to better understand the adipose tissue distribution of other therapeutics currently being tested as part of HIV cure strategies, such as HDAC inhibitors, TLR agonists, or nanoformulated antiretrovirals.
Immunometabolism, Metabolic Reprogramming, and Relevance for HIV Tissue Reservoirs
T h e r e c e n t h e i g h t e n e d i n t e r e s t i n m et a b o l i s m , immunometabolism, and metabolic disorders has led to new concepts with potentially significant relevance for HIV immunology and virology, particularly HIV-infected immune cells in different tissue reservoirs which differ in the regulation of viral replication and latency. Generally, immunometabolism and metabolic reprogramming refer to the regulation of immune cell development, differentiation, and function by systemic metabolism and intracellular metabolic pathways-more specifically, major bioenergetic pathways, including glycolysis, oxidative phosphorylation, and fatty acid oxidation and lipid metabolism [106] [107] [108] [109] [110] [111] [112] [113] . These topics have been extensively reviewed and studied mostly in the context of cancer immunology, but recent studies have begun to demonstrate their importance for HIV replication and pathogenesis. Hegedus et al. showed that glycolysis is essential for HIV replication in primary human CD4 T cells [114] . Extensive studies by the Palmer and Crowe groups have investigated how metabolic pathways such as glucose metabolism and glycolysis influence human T cell and monocyte function and homeostasis, and susceptibility to HIV infection [115] [116] [117] [118] [119] . Activation of mTOR, a major regulator of metabolic pathway utilization and T cell activation, was recently demonstrated by Besnard et al. to be essential for induction of latent HIV in human CD4 T cells [120] . Rasheed et al. showed that HIV replication upregulates lipid metabolism pathways and production of free fatty acids in infected human CD4 T cells, and consistent with this study, Angela et al. showed that fatty acid metabolism through mTOR and PPARγ activation is critical for maximal activation of human CD4 T cells [121, 122] . CD4 T regulatory cells, major regulators of adipose tissue homeostasis as well representing a cellular reservoir for latent HIV, preferentially utilize oxphos and recent studies have demonstrated that Foxp3 promotes activation of oxphos and fatty acid oxidation pathways [123] [124] [125] [126] . The importance of metabolism for HIV pathogenesis is further highlighted by an earlier report by Mansfield et al. demonstrating increased disease progression and death of SIVinfected rhesus macaques fed a high-fat diet of cholesterol and saturated fatty acids [127] . Thus, these metabolic pathways represent another level of epigenetic control of T cell function and survival beyond immunological signals that may explain some differences with respect to HIV replication and persistence in non-lymphoid tissue reservoirs such as adipose tissue. In mice and monkeys, we have observed significant differences in glycolytic and oxphos metabolic phenotypes among T cells in lymphoid and metabolic tissues including blood, lymph nodes, spleen, liver, and adipose tissues (unpublished observations). How these metabolic states influence viral replication versus latency in different tissue reservoirs are the subject of ongoing studies. As these metabolic pathways and mechanisms of immune regulation continue to be elucidated, it may be transformative to see how their application to the HIV field enhances understanding of viral replication, latency, and persistence in tissue reservoirs, as well as advance new therapeutic options.
Conclusions
Traditionally regarded as simple connective tissue with important metabolic functions, the recent explosion of research into metabolism, obesity, immunometabolism, and molecular endocrinology have revealed that adipose tissue is highly dynamic and major regulators of not only metabolism, but immunology, cancer, and microbial pathogenesis. The fact that adipose tissue and adipocytes are often in such intricate association with important HIV tissue reservoirs such as lymph nodes, GALT, liver, thymus, and bone marrow suggests an important role of fat depots for T cell dynamics, HIV pathogenesis, and antiretroviral efficacy in these reservoir sites, and the HIV field will continue to benefit from intensive ongoing research into obesity and metabolism. Future research into the adipose tissue HIV reservoir will hopefully yield more insight into viral latency and replication dynamics in adipose tissue, the contribution of the adipose tissue reservoir to the total body viral load, how the viral reservoir impacts adipose tissue health and function, immunological responses and control of adipose tissue virus, antiretroviral pharmacology in adipose tissue, and the role of metabolic reprogramming of infected immune cells in lymphoid and non-lymphoid tissues.
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